Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Entrada Therapeutics Inc (TRDA)
NASDAQ:TRDA
RESEARCH TOOLSreports
Entrada Therapeutics Inc (TRDA) Stock Price & Analysis
51 Followers
TRDA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.62 - $18.44
Previous Close$14.35
Volume105.31K
Average Volume (3M)77.94K
Market Cap
$482.18M
Enterprise Value$482.80M
Total Cash (Recent Filing)$67.60M
Total Debt (Recent Filing)$68.23M
Price to Earnings (P/E)-56.4
Beta0.53
Next Earnings
May 09, 2024EPS Estimate
-$0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding33,601,103
10 Day Avg. Volume63,569
30 Day Avg. Volume77,936
Standard Deviation0.27
R-Squared0.01
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)1.91
Price to Sales (P/S)11.52
Price to Cash Flow (P/CF)-28.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.74
Enterprise Value/Gross Profit3.74
Enterprise Value/Ebitda26.77
Forecast
1Y Price Target
$21.00Price Target Upside48.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Entrada Therapeutics Inc News
PremiumStock Analysis & Ideas
‘Time to Pull the Trigger,’ Says Oppenheimer About These 3 Stocks
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TRDA FAQ
What was Entrada Therapeutics Inc’s price range in the past 12 months?
Entrada Therapeutics Inc lowest stock price was $10.62 and its highest was $18.44 in the past 12 months.
What is Entrada Therapeutics Inc’s market cap?
Currently, no data Available
When is Entrada Therapeutics Inc’s upcoming earnings report date?
Entrada Therapeutics Inc’s upcoming earnings report date is May 09, 2024 which is in 13 days.
How were Entrada Therapeutics Inc’s earnings last quarter?
Entrada Therapeutics Inc released its earnings results on Mar 13, 2024. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.168 by -$0.122.
Is Entrada Therapeutics Inc overvalued?
According to Wall Street analysts Entrada Therapeutics Inc’s price is currently Undervalued.
Does Entrada Therapeutics Inc pay dividends?
Entrada Therapeutics Inc does not currently pay dividends.
What is Entrada Therapeutics Inc’s EPS estimate?
Entrada Therapeutics Inc’s EPS estimate is -$0.59.
How many shares outstanding does Entrada Therapeutics Inc have?
Entrada Therapeutics Inc has 33,601,105 shares outstanding.
What happened to Entrada Therapeutics Inc’s price movement after its last earnings report?
Entrada Therapeutics Inc reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.168. Following the earnings report the stock price went up 9.758%.
Which hedge fund is a major shareholder of Entrada Therapeutics Inc?
Among the largest hedge funds holding Entrada Therapeutics Inc’s share is Baker Bros Advisors LP. It holds Entrada Therapeutics Inc’s shares valued at 73M.
---
Entrada Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.00 (48.20% Upside)
$21.00 (48.20% Upside)
Insider Transactions
Bought Shares
Worth $176.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 14.1%
Last 30 Days ▲ 14.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.01%
12-Months-Change
Fundamentals
Return on Equity
-2.94%
Trailing 12-Months
Asset Growth
86.15%
Trailing 12-Months
Company Description
Entrada Therapeutics Inc
Entrada Therapeutics Inc mission is to transform the treatment of devastating diseases and improve patients quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases.
---
TRDA Stock 12 Months Forecast
Average Price Target
$21.00
▲(48.20% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Arvinas Holding Company
―
Avrobio
―
Intellia Therapeutics
―
Best Analysts Covering TRDA
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
+7.53%
reiterated a buy rating last month
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +7.53% per trade.
---